Ignite Creation Date:
2024-05-05 @ 10:19 PM
Last Modification Date:
2024-10-26 @ 10:17 AM
Study NCT ID:
NCT01088893
Status:
UNKNOWN
Last Update Posted:
2012-05-24
First Post:
2009-08-11
Brief Title:
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
Sponsor:
Organisation for Oncology and Translational Research
Organization:
Organisation for Oncology and Translational Research
Study Overview
Official Title:
A Randomized Study of mTOR Inhibition by RAD001 Everolimus in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline andor Taxane-based Chemotherapy
Status:
UNKNOWN
Status Verified Date:
2012-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy
Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment anthracycline andor taxane-based and before surgery The patients will be monitored for efficacy and safety
Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment anthracycline andor taxane-based and before surgery The patients will be monitored for efficacy and safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None